Skip to main content
Annals of Intensive Care

Table 3 Univariate analysis of factors associated with 1-year mortality

From: Critically ill metastatic cancer patients returning home after unplanned ICU stay: an observational, multicentre retrospective study

 

HR

95% CI

p

Age, per year

1.01

1.00–1.03

0.059

Female gender

0.67

0.50–0.90

0.008

Charlson Comorbidity Index

1.05

0.96–1.13

0.290

Performance Status 1 month before ICU admission

 0–1

0.46

0.34–0.63

0.001

 Malnutrition

2.08

1.47–2.70

0.001

 Albumin on day 1

0.97

0.95–1.00

0.079

Primary tumour site

 Lung, non-small cell

1.26

0.93–1.71

0.14

 Lung, small cell

1.14

0.62–2.10

0.67

 Breast

0.55

0.35–0.87

0.010

 Colorectal

1.19

0.73–1.93

0.49

 Kidney

1.776

0.961–3.281

0.067

 Prostate

0.49

0.20–1.18

0.113

 Stomach

1.545

0.725–3.291

0.260

 Pancreas

1.333

0.425–4.176

0.622

 Bladder

1.065

0.5–2.268

0.87

Metastatic site

  Lung/pleura

0.97

0.72–1.32

0.86

  Bone

0.93

0.69–1.25

0.62

  Liver

1.42

1.06–1.91

0.019

  Adrenal gland

1.32

0.86–2.03

0.20

Metastatic sites, n

1.07

0.94–1.22

0.30

LDH on day 1 (UI/L)

1.002

1–1.004

0.024

Antineoplastic therapy before ICU admission

 Cytostatic chemotherapy

0,55

0.40–0.74

 < 0.001

 Hormone therapy

0.58

0.37–0.93

0.024

 Targeted therapy/immunotherapy

0.88

0.65–1.19

0.403

 Radiotherapy

0.55

0.38–0.79

0.001

 No previous treatment

2.13

1.55–2.92

 < 0.001

Lines of antineoplastic therapy before admission

0.83

0.74–0.93

0.002

Reason for ICU admission

 Acute respiratory failure

1.42

1.05–1.91

0.024

 Septic shock

1.34

0.94–1.89

0.102

 Coma

1.07

0.72–1.59

0.75

 Acute renal failure

1.11

0.71–1.74

0.64

 Life-threatening metabolic complication

0.63

0.35–1.13

0.119

 Hypercapnic respiratory failure

1.12

0.64–1.97

0.696

 Severe bleeding

0.80

0.39–1.63

0.538

 Multiple organ failure

4.30

2.21–8.82

 < 0.001

Etiological diagnosis

 Infection

0.93

0.69–1.23

0.600

 Specific, related to the underlying cancer

1.31

0.97–1.76

0.074

 Pleural effusion

1.01

0.68–1.52

0.952

 Anti-neoplastic drug side effect

0.76

0.44–1.32

0.092

 Cardiogenic pulmonary oedema/cardiac failure

1.34

0.73–2.46

0.3511

 Aspiration pneumonitis

1.38

0.68–2.80

0.375

 Pulmonary embolism

1.37

0.64–2.91

0.421

 Pericardial effusion, cardiac tamponade

0.67

0.25–1.79

0.421

Organ failure supports

 Vasopressors

1.35

1.01–1.81

0.046

 Mechanical ventilation

1.47

1.05–2.05

0.024

 Renal replacement therapy

2.52

1.18–5.41

0.017

SAPS II

1.03

1.02–1.04

0.001

SOFA score on day 1

1.09

1.05–1.14

0.001

SOFA score > 5 on day 1

1.86

1.39–2.49

 < 0.001

∆ SOFA d1–d3

0.89

0.85–0.94

 < 0.001

ONCOSCORE

1.11

1.04–1.19

0.003

Severe neutropenia on day 1

0.67

0.35–1.26

0.215

Thrombocytopenia on day 1

0.95

0.68–1.34

0.776

Time since first symptoms, d

1.00

0.98–1.01

0.551

ICU LOS, d

0.99

0.96–1.01

0.292

DFLST before ICU admission

0.91

0.29–2.84

0.868

DFLST during ICU stay

3.67

2.73–4.99

 < 0.001

  1. HR hazard ratio, 95% CI 95% confidence interval, ICU Intensive Care Unit, LDH lactate dehydrogenase, SAPS II Simplified Acute Physiology Score II, SOFA Sequential Organ Failure Assessment, LOS Length of Stay, DFLST Decisions to forgo life-sustaining therapies
Back to article page